Loading
A phase 3 trial of Somatostatin analogues and Pegvisomant in Pituitary tumours, run by Ipsen, completed.
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients is a phase 3 interventional study registered as NCT00383708 by Ipsen, with 125 participants recorded, started 2006-10 and reaching its primary completion in 2008-10. Interventions recorded: lanreotide (Autogel formulation), Pegvisomant. Conditions recorded: Acromegaly.
Linked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
125 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2018-07-23), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Periodprimary | Lanreotide Autogel + Pegvisomant Co-administration | 57 | 57.9% | - | <0.0001 | link |
Shares Pegvisomant, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pegvisomant, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Somatostatin analogues (octreotide, lanreotide), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.